Core Viewpoint - Rongjie Health's main supply chain for its U.S. subsidiary is sourced from China, and the company is currently evaluating measures to potentially shift its supply chain [1] Summary by Relevant Sections - **Sales to the U.S.**: In 2024, the company's sales to the U.S. are projected to be $61.985 million, with $5.3234 million coming from domestic factory exports and $56.6615 million from sales made by the U.S. subsidiary [1] - **Product Classification**: The far-infrared sauna rooms sold to the U.S. are classified as wood products and do not qualify for the "reciprocal tariff" exemption [1] - **Supply Chain Assessment**: The company is assessing measures related to the potential transfer of its supply chain [1]

Financial Performance - The company's basic earnings per share decreased by 5.13% to 1.11 yuan in 2024 from 1.17 yuan in 2023 [1] - The net profit for 2024 was 1.92 billion yuan, down 5.42% from 2.03 billion yuan in 2023 [1] - The operating revenue fell by 13.91% to 15.97 billion yuan in 2024 compared to 18.55 billion yuan in 2023 [1] - The return on equity decreased to 9.64% in 2024 from 10.50% in 2023, reflecting an 8.19% decline [1] - The net asset per share dropped by 19.84% to 11.11 yuan in 2024 from 13.86 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 10,732.22 million shares, accounting for 60.5% of the circulating shares, with a decrease of 1.0964 million shares compared to the previous period [2] - The largest shareholder, Lin Qi, holds 4,537.03 million shares, representing 25.58% of the total share capital, with no change [3] - New entry in the top ten shareholders includes Xu Haipeng, holding 132.00 million shares, representing 0.74% [3] Dividend Distribution - The company announced a dividend distribution plan of 10 yuan per share, including tax [2]